Close Menu

This story has been updated from a previous version to include information about the platorms on which Cepheid's test can be run.

NEW YORK – The US Food and Drug Administration on Friday issued Emergency Use Authorization for Cepheid's Xpert Xpress SARS-CoV-2 test for diagnosing COVID-19.

It is the first EUA for a SARS-CoV-2 that can be used at the point of care. In addition to high- and moderate-complexity laboratories, the rapid molecular test can be used in certain patient-care settings, the agency said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.